MBX
NASDAQMBX Biosciences Inc.
Price$30.63-0.88 (-2.79%)
2026-03-052026-06-08
News · 26 weeks67-58%
2025-12-142026-06-07
Mix4590d
- SEC Filings20(44%)
- Insider15(33%)
- Other5(11%)
- Leadership4(9%)
- Earnings1(2%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Mathers Edward T4 - MBX Biosciences, Inc. (0001776111) (Issuer)
- INSIDERSEC Form 4 filed by Director Pescovitz Ora H.4 - MBX Biosciences, Inc. (0001776111) (Issuer)
- INSIDERSEC Form 4 filed by Director Heron Patrick J4 - MBX Biosciences, Inc. (0001776111) (Issuer)
- INSIDERSEC Form 4 filed by Director Stelzer Laurie4 - MBX Biosciences, Inc. (0001776111) (Issuer)
- INSIDERSEC Form 4 filed by Director Hoerter Steven L.4 - MBX Biosciences, Inc. (0001776111) (Issuer)
- INSIDERSEC Form 4 filed by Director Ryder Steven4 - MBX Biosciences, Inc. (0001776111) (Issuer)
- INSIDERSEC Form 4 filed by Director Aynechi Tiba4 - MBX Biosciences, Inc. (0001776111) (Issuer)
- SECMBX Biosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders8-K - MBX Biosciences, Inc. (0001776111) (Filer)
- PRMBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026CARMEL, Ind., June 01, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will host an investor webcast and conference call at 8:00 am ET on Friday, June 12, 2026 to discuss presentations for once-weekly canvuparatide at the upcoming Endocrine Society's Annual Meeting (ENDO 2026) in Chicago. One-year open-label extension (OLE) data from the Phase 2 trial of once-weekly canvuparatide will be presented at the 3rd Parathyroid Summit during ENDO 2026 on Friday, June
- PRMBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York CityCARMEL, Ind. and BURLINGTON, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at the Jefferies 2026 Global Healthcare Conference in New York City. The presentation will take place on Wednesday, June 3, 2026, from 8:10 a.m. to 8:40 a.m. ET. The live webcast can be accessed under the Events section of the MBX Biosciences website at https:/
- SECSEC Form 144 filed by MBX Biosciences Inc.144 - MBX Biosciences, Inc. (0001776111) (Subject)
- INSIDERChief Medical Officer Azoulay Salomon exercised 70,003 shares at a strike of $11.65 and sold $2,685,515 worth of shares (70,003 units at $38.36) as part of a pre-agreed trading plan (SEC Form 4)4 - MBX Biosciences, Inc. (0001776111) (Issuer)
- SECSEC Form 144 filed by MBX Biosciences Inc.144 - MBX Biosciences, Inc. (0001776111) (Subject)
- SECMBX Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - MBX Biosciences, Inc. (0001776111) (Filer)
- PRMBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly DosingPreliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, including 2 placebo) MBX 4291 generally well tolerated, only one event of diarrhea, nausea or vomiting through 8 weeks in first MAD Part B cohort MBX 4291 12-week Phase 1 MAD Part C data remain on track for Q4 2026 MBX 5765 nominated as amycretin prodrug development candidate, a novel GLP-1 / GIP / glucagon / DACRA agonist designed for once-monthly dosing, superior efficacy and improved tolerability Imapextide Phase 2a STEADI™ trial results demonstrate positive proof of concept in post-bariatric hypoglycemia (PBH) Company to host in-person and
- SECSEC Form DEFA14A filed by MBX Biosciences Inc.DEFA14A - MBX Biosciences, Inc. (0001776111) (Filer)
- INSIDERChief Medical Officer Azoulay Salomon sold $6,824 worth of shares (231 units at $29.54), decreasing direct ownership by 2% to 14,769 units (SEC Form 4) (withholding obligation)4 - MBX Biosciences, Inc. (0001776111) (Issuer)
- INSIDERPresident & CEO Hawryluk P. Kent sold $17,931 worth of shares (607 units at $29.54), decreasing direct ownership by 0.08% to 727,667 units (SEC Form 4) (for withholding tax)4 - MBX Biosciences, Inc. (0001776111) (Issuer)
- SECSEC Form 144 filed by MBX Biosciences Inc.144 - MBX Biosciences, Inc. (0001776111) (Subject)
- SECSEC Form 144 filed by MBX Biosciences Inc.144 - MBX Biosciences, Inc. (0001776111) (Subject)
- SECMBX Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - MBX Biosciences, Inc. (0001776111) (Filer)
- SECSEC Form 10-Q filed by MBX Biosciences Inc.10-Q - MBX Biosciences, Inc. (0001776111) (Filer)
- PRMBX Biosciences Reports First Quarter 2026 Financial Results and Corporate HighlightsResults from Phase 2 trial of once-weekly canvuparatide accepted for oral presentation at ENDO in June 2026 Phase 3 trial of once-weekly canvuparatide on track to initiate in Q3 2026 Appointment of Mark Soued as Chief Commercial Officer adds launch and commercialization expertise Company to host Obesity Day on May 11th featuring initial blinded data from ongoing MBX 4291 Phase 1 trial and update on expanding obesity portfolio $440.0 million in cash and investments expected to support operations into 2029 CARMEL, Ind. and BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, developme
- PRMBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant AwardCARMEL, Ind. and BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Mark R. Soued, MBA, as Chief Commercial Officer (CCO). Mr. Soued brings more than two decades of commercial leadership across global biopharmaceutical organizations, with deep expertise in product launches, market access, and building high-performing commercial teams. "Mark is an exceptional commercial leader with a demonstrated ability to build and scale c
- SECSEC Form 144 filed by MBX Biosciences Inc.144 - MBX Biosciences, Inc. (0001776111) (Subject)
MBX FAQ
6 questionsWhere does MBX stock trade?
MBX Biosciences Inc. (MBX) is listed on NASDAQ.What sector and industry is MBX in?
MBX Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did MBX Biosciences Inc. go public?
MBX Biosciences Inc. (MBX) completed its IPO in 2024.What are analysts saying about MBX?
MBX Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight on 2026-01-28. Recent price targets range from $1800.00 to $3800.00.What companies are similar to MBX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare MBX side-by-side with any of them on Quantisnow.How can I track MBX on Quantisnow?
Quantisnow aggregates MBX Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MBX to receive live email and push alerts on every new disclosure.